Zhuoming Liu

Zhuoming Liu

Auto-generated profile, based on publicly available information

Zhuoming Liu

Department of Molecular Microbiology, Washington University in Saint Louis, St. Louis, MO 63110

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2020 in Science Immunology
Verified
Journal Article
Open access
PDF file
RZRuochen Zang
Ruochen Zang
MCMaria Florencia Gomez Castro
Maria Florencia Gomez Castro
BMBroc T. McCune
Broc T. McCune
QZQiru Zeng
Qiru Zeng
PRPaul W. Rothlauf
Paul W. Rothlauf
SDSiyuan Ding
Siyuan Ding
Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA are frequently observed in COVID-19. However, it is unclear whether SARS-CoV-2 replicates in the human intestine and contributes to possible fecal-oral transmission. Here, we report productive infection of SARS-CoV-2 in ACE2+ mature enterocytes in human small intestinal enteroids. Expression of two mucosa-specific serine proteases, TMPRSS2 and TMPRSS4, facilitated SARS-CoV-2 spike fusogenic activity and promoted virus entry into host cells. We also demonstrate that viruses released into the intestinal lumen were inactivated by simulated human colonic fluid, and infectious virus was not recovered from the stool specimens of patients with COVID-19. Our results highlight the intestine as a potential site of SARS-CoV-2 replication, which may contribute to local and systemic illness and overall disease progression.

14 July 2021 in Nature
Verified
Journal Article
Closed access
PDF file
TSTyler N. Starr
Tyler N. Starr
NCNadine Czudnochowski
Nadine Czudnochowski
ZLZhuoming Liu
Zhuoming Liu
FZFabrizia Zatta
Fabrizia Zatta
YPYoung-Jun Park
Young-Jun Park
GSGyorgy Snell
Gyorgy Snell

1 September 2020 in Cell Host & Microbe
Verified
Journal Article
Closed access
JCJames Brett Case
James Brett Case
PRPaul W. Rothlauf
Paul W. Rothlauf
RCRita E. Chen
Rita E. Chen
ZLZhuoming Liu
Zhuoming Liu
HZHaiyan Zhao
Haiyan Zhao
SWSean P.J. Whelan
Sean P.J. Whelan

15 February 2022 in Nature
Verified
Journal Article
Closed access
PDF file
WKWooseob Kim
Wooseob Kim
Julian Q ZhouJulian Q Zhou
Julian Q Zhou
SHStephen C. Horvath
Stephen C. Horvath
ASAaron J. Schmitz
Aaron J. Schmitz
ASAlexandria J. Sturtz
Alexandria J. Sturtz
AEAli Ellebedy
Ali Ellebedy

1 November 2021 in Annals of Internal Medicine
Verified
Journal Article
Open access
PDParakkal Deepak
Parakkal Deepak
WKWooseob Kim
Wooseob Kim
MPMichael A. Paley
Michael A. Paley
MYMonica Yang
Monica Yang
ACAlexander B. Carvidi
Alexander B. Carvidi
AKAlfred Kim
Alfred Kim
Evidence suggests that immunogenicity to mRNA-based SARS-CoV-2 vaccination in immunosuppressed patients may be reduced. This study assessed the response to 2 doses of mRNA-based SARS-CoV-2 vaccine ... Visual Effect of Immunosuppression on Immunogenicity of mRNA SARS-CoV-2 Vaccines. Evidence suggests that immunogenicity to mRNA-based SARS-CoV-2 vaccination in immunosuppressed patients ma... Background: Patients with chronic inflammatory disease (CID) treated with immunosuppressive medications have increased risk for severe COVID-19. Although mRNA-based SARS-CoV-2 vaccination provides ...

19 July 2021 in Nature
Verified
Journal Article
Open access
PDF file
MTM. Alejandra Tortorici
M. Alejandra Tortorici
NCNadine Czudnochowski
Nadine Czudnochowski
TSTyler N. Starr
Tyler N. Starr
RMRoberta Marzi
Roberta Marzi
AWAlexandra C. Walls
Alexandra C. Walls
MPMatteo Samuele Pizzuto
Matteo Samuele Pizzuto
The recent emergence of SARS-CoV-2 variants of concern1,2,3,4,5,6,7,8,9,10 and the recurrent spillovers of coronaviruses11,12 into the human population highlight the need for broadly neutralizing antibodies that are not affected by the ongoing antigenic drift and that can prevent or treat future zoonotic infections. Here we describe a human monoclonal antibody designated S2X259, which recognizes a highly conserved cryptic epitope of the receptor-binding domain and cross-reacts with spikes from all clades of sarbecovirus. S2X259 broadly neutralizes spike-mediated cell entry of SARS-CoV-2, including variants of concern (B.1.1.7, B.1.351, P.1, and B.1.427/B.1.429), as well as a wide spectrum of human and potentially zoonotic sarbecoviruses through inhibition of angiotensin-converting enzyme 2 (ACE2) binding to the receptor-binding domain. Furthermore, deep-mutational scanning and in vitro escape selection experiments demonstrate that S2X259 possesses an escape profile that is limited to a single substitution, G504D. We show that prophylactic and therapeutic administration of S2X259 protects Syrian hamsters (Mesocricetus auratus) against challenge with the prototypic SARS-CoV-2 and the B.1.351 variant of concern, which suggests that this monoclonal antibody is a promising candidate for the prevention and treatment of emergent variants and zoonotic infections. Our data reveal a key antigenic site that is targeted by broadly neutralizing antibodies and will guide the design of vaccines that are effective against all sarbecoviruses.